PMID: 11328774May 1, 2001Paper

Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae

The Journal of Antimicrobial Chemotherapy
F López FornasM Valdés Chávarri

Abstract

The efficacy of different antibiotics was compared in an experimental model of aortic valve endocarditis in rabbits, using a serotype 19 strain of Streptococcus pneumoniae resistant to penicillin (MIC 12 mg/L) and ceftriaxone (MIC 12 mg/L). The results were compared with those of a control group, which received no treatment. One hundred and nineteen animals were treated with one of the following antibiotic regimens: im procaine penicillin G at a dosage of 300,000 U/kg weight/12 h (16 animals); iv trovafloxacin, 13.3 mg/kg/12 h (31 animals); iv ceftriaxone, 75 mg/kg/24 h (21 animals); iv vancomycin, 20 mg/kg/12 h (15 animals) and im quinupristin-dalfopristin, 30 mg/kg/8 h (20 animals). All the antibiotics used in this study proved to be efficient in reducing numbers of S. pneumoniae and in increasing the percentage of aortic vegetations that were rendered sterile compared with the control group. Penicillin at the dosage used in our study was capable of achieving serum concentrations two or three times greater than the MIC, thus demonstrating its effectiveness as an antibiotic for this endocarditis model. No significant difference was observed between the effects of vancomycin, quinupristin-dalfopristin and penicillin. Vancomycin...Continue Reading

References

Jul 1, 1992·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N X Chin, H C Neu
Jul 1, 1992·The Journal of Antimicrobial Chemotherapy·S G AmyesJ Hood
Oct 1, 1992·Antimicrobial Agents and Chemotherapy·L K McDougalF C Tenover
Sep 1, 1986·Reviews of Infectious Diseases·W G PowderlyG Medoff
Sep 1, 1966·Archives of Internal Medicine·A L Straus, M Hamburger
Dec 1, 1983·British Heart Journal·R BaylissS E Young
Aug 11, 1994·The New England Journal of Medicine·I R Friedland, G H McCracken
May 1, 1994·Antimicrobial Agents and Chemotherapy·M L Fernández GuerreroF Soriano
Nov 1, 1996·Journal of Clinical Microbiology·A FerroniP Berche
Feb 1, 1997·Antimicrobial Agents and Chemotherapy·K S ThomsonS L Block
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·H M Taylor, J B Bingham
Dec 24, 1997·Chest·C S BryanM S Stinson
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S I AroninE L Cooney
May 1, 1997·The Journal of Antimicrobial Chemotherapy·E Rubinstein, F Bompart
Oct 3, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D PontaniJ Johnson
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G V DoernR N Jones
Nov 25, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I LutsarI R Friedland

❮ Previous
Next ❯

Citations

Jul 3, 2002·Infectious Disease Clinics of North America·Bruno Hoen
Aug 21, 2002·Expert Opinion on Pharmacotherapy·Joseph M Blondeau, Stephen E Sanche
Sep 15, 2015·Journal of Epidemiology and Global Health·Yagob AlmazrouWilliam P Hausdorff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.